BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Remicade (infliximab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Remicade (infliximab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05906576-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT05906576)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Crohn's Disease.\nStudy: Post
 -marketing Registry Study of Infliximab for Injection in Chinese Pediatric
  Crohn's Disease Patients\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05906576
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839820-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT06839820)
DESCRIPTION:Remicade (infliximab)\, phase na\, Ulcerative Colitis.\nStudy: 
 Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06839820
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03684278-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT03684278)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Randomised Treatment o
 f Acute Pancreatitis With Infliximab: Double-blind\, Placebo-controlled\, 
 Multi-centre Trial (RAPID-I)\nEstimated primary completion: 15 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03684278
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06064864-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT06064864)
DESCRIPTION:Remicade (infliximab)\, phase na\, Crohn's Disease.\nStudy: Eff
 icacy and Safety of Formulation Switching Between SC Infliximab and IV Inf
 liximab in Patients With CD\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06064864
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05689879-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT05689879)
DESCRIPTION:Remicade (infliximab)\, phase 3.\nStudy: Evaluation of TNF-alph
 a Antagonists (Infliximab) Withdrawal in Sarcoidosis\nEstimated primary co
 mpletion: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/infliximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05689879
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06758024-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT06758024)
DESCRIPTION:Remicade (infliximab)\, phase na\, Ulcerative Colitis.\nStudy: 
 PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory
  Bowel Disease\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06758024
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180994-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Remicade (infliximab): Phase 1/2 readout est. (NCT05180994)
DESCRIPTION:Remicade (infliximab)\, phase 1/2.\nStudy: Topical Infliximab i
 n Eyes With Penetrating Keratoplasty\nEstimated primary completion: 1 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051809
 94
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT05034536)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: PD-1 Antibody Therapy 
 + Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050345
 36
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941376-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT06941376)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Pragmatic\, Open-Label
  Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06941376
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05928039-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT05928039)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Crohn's Disease.\nStudy: PATH
 FINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-
 to-Severely Active Ileal-dominant Crohn's Disease\nEstimated primary compl
 etion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 infliximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05928039
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491913-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07491913)
DESCRIPTION:Remicade (infliximab)\, phase na.\nStudy: Biologic Treatment Wi
 thdrawal in Takayasu Arteritis Patients in Sustained Remission\nEstimated 
 primary completion: 15 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07491913
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657312-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT07657312)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Infliximab for Cytokin
 e Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy i
 n Patients With Relapsed or Refractory Myeloma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /infliximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07657312
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257068-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07257068)
DESCRIPTION:Remicade (infliximab)\, phase na.\nStudy: Checkpoint Inhibitor 
 Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Proje
 ct: A Pilot Study\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07257068
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Immunosuppressant Mana
 gement in Rheumatology Patients Undergoing Elective Total Shoulder Arthrop
 lasty\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470502-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280213
DTEND;VALUE=DATE:20280214
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07470502)
DESCRIPTION:Remicade (infliximab)\, phase na\, Ulcerative Colitis.\nStudy: 
 MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease\nEstima
 ted primary completion: 13 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07470502
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671222-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT07671222)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Safety and Efficacy of
  Topical Infliximab in Autoimmune Dry Eye Disease\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/in
 fliximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07671222
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05823532-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT05823532)
DESCRIPTION:Remicade (infliximab)\, phase 4.\nStudy: Anti-Inflammatory Chal
 lenge in Schizophrenia\nEstimated primary completion: March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05823532
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614387-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Remicade (infliximab): Phase 3 readout est. (NCT06614387)
DESCRIPTION:Remicade (infliximab)\, phase 3\, Ulcerative Colitis.\nStudy: V
 edolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab\nEs
 timated primary completion: 30 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06614387
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02638701-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Remicade (infliximab): Phase 1/2 readout est. (NCT02638701)
DESCRIPTION:Remicade (infliximab)\, phase 1/2.\nStudy: Infliximab Therapy f
 or Dolichoectactic Vertebrobasilar Aneurysms\nEstimated primary completion
 : June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inflixim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 2638701
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT06031233)
DESCRIPTION:Remicade (infliximab)\, phase 4.\nStudy: Evaluating the Safety 
 of Shortened Infusion Times for dIfferent Oncological Immunotherapie\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06031233
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176754-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07176754)
DESCRIPTION:Remicade (infliximab)\, phase na.\nStudy: TNF-α Antagonists Mi
 tigate Systemic Inflammatory Response After Cardiac Arrest.\nEstimated pri
 mary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/infliximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07176754
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136546-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT06136546)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Cognitive Dysfunction 
 and Inflammation in Depression: Experimental Inhibition Via Infliximab\nEs
 timated primary completion: 31 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06136546
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149441-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07149441)
DESCRIPTION:Remicade (infliximab)\, phase na\, Ulcerative Colitis.\nStudy: 
 Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disea
 se: an Open-label Randomized Controlled Study\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 infliximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07149441
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424040-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07424040)
DESCRIPTION:Remicade (infliximab)\, phase na\, Crohn's Disease.\nStudy: The
  Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn'
 s Disease in Children\nEstimated primary completion: 30 November 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07424040
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510191-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07510191)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Crohn's Disease.\nStudy: TNFi
  Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease Wit
 h Suboptimal Response\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07510191
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683975-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07683975)
DESCRIPTION:Remicade (infliximab)\, phase 4.\nStudy: Infliximab for Immune 
 Checkpoint Inhibitor Associated AKI\nEstimated primary completion: 15 Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0768
 3975
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415473-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07415473)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Crohn's Disease.\nStudy: Akke
 rmansia Muciniphila Combined With Infliximab for Promoting Intestinal Muco
 sal Healing in Crohn's Disease\nEstimated primary completion: 31 March 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07415473
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417696-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07417696)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Crohn's Disease.\nStudy: Palm
 itoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Hea
 ling in Crohn's Disease\nEstimated primary completion: 31 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07417696
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314606-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT07314606)
DESCRIPTION:Remicade (infliximab)\, phase na\, Crohn's Disease.\nStudy: Com
 bining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients 
 With Crohn's Disease\nEstimated primary completion: 1 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07314606
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584228-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Remicade (infliximab): Phase na readout est. (NCT05584228)
DESCRIPTION:Remicade (infliximab)\, phase na\, Crohn's Disease.\nStudy: Med
 ical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease\n
 Estimated primary completion: 1 April 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/infliximab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05584228
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Psoriasis.\nStudy: Utilizatio
 n of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary 
 completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/infliximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07352566
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576452-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Remicade (infliximab): Phase 4 readout est. (NCT07576452)
DESCRIPTION:Remicade (infliximab)\, phase 4\, Ulcerative Colitis.\nStudy: F
 irST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised 
 Controlled Trial\nEstimated primary completion: 1 June 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/infliximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07576452
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04305145-9@assetmemo.bio
DTSTAMP:20261121T005658Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Remicade (infliximab): Phase 2 readout est. (NCT04305145)
DESCRIPTION:Remicade (infliximab)\, phase 2.\nStudy: Infliximab for Treatme
 nt of Immune Checkpoint Inhibitor Colitis\nEstimated primary completion: 3
 0 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inflixim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4305145
URL:https://assetmemo.bio/drug/infliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
